Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||BMS-986012 + Carboplatin + Etoposide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BMS-986012||BMS-986012 is a monoclonal antibody that binds to the ganglioside fucosyl-GM1, which may lead to anti-tumor immune response (PMID: 30021910).|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 7||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Etoposide||Vepesid||EPEG|Eposin|VP-16|VP-16-213||TOPO2 inhibitor 5||Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02815592||Phase Ib/II||Etoposide BMS-986012 + Cisplatin + Etoposide BMS-986012 + Carboplatin + Etoposide||Trial of BMS-986012 in Combination With Platinum and Etoposide||Active, not recruiting||ESP||0|